A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects With Extensive Stage Small Cell Lung Cancer (MERU)
Phase of Trial: Phase III
Latest Information Update: 06 Feb 2019
At a glance
- Drugs Rovalpituzumab tesirine (Primary) ; Dexamethasone
- Indications Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms MERU
- Sponsors AbbVie; AbbVie Germany
- 29 Jan 2019 Planned End Date changed from 6 Sep 2021 to 29 Oct 2021.
- 20 Dec 2018 Planned End Date changed from 31 Aug 2021 to 6 Sep 2021.
- 28 Nov 2018 Planned End Date changed from 31 Aug 2020 to 31 Aug 2021.